Pharsight

Zulresso is owned by Sage Therap.

Zulresso contains Brexanolone.

Zulresso has a total of 8 drug patents out of which 0 drug patents have expired.

Zulresso was authorised for market use on 17 June, 2019.

Zulresso is available in solution;intravenous dosage forms.

Zulresso can be used as method of treating postpartum depression.

Drug patent challenges can be filed against Zulresso from 2023-06-18.

The generics of Zulresso are possible to be released after 08 March, 2037.

Application	Filing Date	Opposition Party	Legal Status
EP13740743A	2020-07-08	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9200088	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9750822	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US8410077	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US10117951	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US10322139	SAGE THERAP	Neuroactive steroid formulations and methods of treating CNS disorders	Jan, 2033 (9 years from now)
US10251894	SAGE THERAP	Anticonvulsant activity of steroids	Nov, 2033 (10 years from now)
US10940156	SAGE THERAP	Neuroactive steroids, compositions, and uses thereof	Mar, 2037 (13 years from now)